Biomarin Pharmaceutical Inc (BMRN)

Return on total capital

Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 689,643 850,797 685,960 554,102 407,044 315,083 253,938 205,304 165,948 123,275 87,420 164,953 116,157 71,092 50,355 -60,606 -32,721 -42,050 -94,770 -13,535
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 6,056,710 6,027,110 5,793,460 5,657,990 5,413,400 5,286,300 5,073,820 4,951,550 4,896,900 4,782,830 4,659,040 4,603,160 4,568,510 4,504,810 4,391,320 4,270,740 4,266,150 4,241,570 4,162,010 4,106,000
Return on total capital 11.39% 14.12% 11.84% 9.79% 7.52% 5.96% 5.00% 4.15% 3.39% 2.58% 1.88% 3.58% 2.54% 1.58% 1.15% -1.42% -0.77% -0.99% -2.28% -0.33%

September 30, 2025 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $689,643K ÷ ($—K + $6,056,710K)
= 11.39%


Peer comparison

Sep 30, 2025

Company name
Symbol
Return on total capital
Biomarin Pharmaceutical Inc
BMRN
11.39%
Arrowhead Pharmaceuticals Inc
ARWR
17.83%
Regeneron Pharmaceuticals Inc
REGN
16.76%